[1] Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature reviews Cancer. 2010;10:760-74.
[2] Wei L, Sun JJ, Cui YC, Jiang SL, Wang XW, Lv LY, et al. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:9979-87.
[3] Prabhu VV, Devaraj SN. KAI1/CD82, Metastasis Suppressor Gene as a Therapeutic Target for Non-Small-Cell Lung Carcinoma. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer. 2017;36:269-75.
[4] Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Laboratory investigation; a journal of technical methods and pathology. 2006;86:1203-7.
[5] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine. 1997;3:730-7.
[6] Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell death and differentiation. 2008;15:504-14.
[7] Yi SY, Nan KJ. Tumor-initiating stem cells in liver cancer. Cancer biology & therapy. 2008;7:325-30.
[8] Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods in molecular biology. 2009;568:161-73.
[9] Su J, Wu S, Wu H, Li L, Guo T. CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/beta-catenin-FoxM1-Twist signaling. Molecular carcinogenesis. 2016;55:1962-73.
[10] Jiang P, Xu C, Chen L, Chen A, Wu X, Zhou M, et al. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells. Molecular carcinogenesis. 2018;57:1835-44.
[11] Jiang P, Xu H, Xu C, Chen A, Chen L, Zhou M, et al. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway. Chemico-biological interactions. 2018;296:154-61.
[12] Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, et al. Heme induces ubiquitination and degradation of the transcription factor Bach1. Molecular and cellular biology. 2007;27:6962-71.
[13] Warnatz HJ, Schmidt D, Manke T, Piccini I, Sultan M, Borodina T, et al. The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycle. The Journal of biological chemistry. 2011;286:23521-32.
[14] Zhou Y, Wu H, Zhao M, Chang C, Lu Q. The Bach Family of Transcription Factors: A Comprehensive Review. Clinical reviews in allergy & immunology. 2016;50:345-56.
[15] Davudian S, Mansoori B, Shajari N, Mohammadi A, Baradaran B. BACH1, the master regulator gene: A novel candidate target for cancer therapy. Gene. 2016;588:30-7.
[16] Liang Y, Wu H, Lei R, Chong RA, Wei Y, Lu X, et al. Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. The Journal of biological chemistry. 2012;287:33533-44.
[17] Nie E, Jin X, Wu W, Yu T, Zhou X, Zhi T, et al. BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. Scientific reports. 2016;6:39743.
[18] Shirjang S, Mansoori B, Mohammadi A, Shajari N, P HGD, Najafi S, et al. miR-330 Regulates Colorectal Cancer Oncogenesis by Targeting BACH1. Advanced pharmaceutical bulletin. 2020;10:444-51.
[19] Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell. 2019;178:316-29 e18.
[20] Wiel C, Le Gal K, Ibrahim MX, Jahangir CA, Kashif M, Yao H, et al. BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 2019;178:330-45 e22.
[21] Wang X, Adjei AA. Lung cancer and metastasis: new opportunities and challenges. Cancer metastasis reviews. 2015;34:169-71.
[22] Mohammadzadeh R, Saeid Harouyan M, Ale Taha SM. Silencing of bach1 gene by small interfering RNA-mediation regulates invasive and expression level of miR-203, miR-145, matrix metalloproteinase-9, and CXCR4 receptor in MDA-MB-468 breast cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017;39:1010428317695925.
[23] Davudian S, Shajari N, Kazemi T, Mansoori B, Salehi S, Mohammadi A, et al. BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;84:191-8.
[24] Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Molecular cell. 2014;55:904-15.
[25] Fang M, Hutchinson L, Deng A, Green MR. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:1250-5.
[26] Yan Y, Zuo X, Wei D. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem cells translational medicine. 2015;4:1033-43.
[27] Wang L, Zuo X, Xie K, Wei D. The Role of CD44 and Cancer Stem Cells. Methods in molecular biology. 2018;1692:31-42.
[28] Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PloS one. 2010;5:e14062.
[29] Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochimica et biophysica acta. 2010;1802:396-405.
[30] Vincent JM, Wack RP, Person DA, Bass JW. Pertussis as the cause of recurrent bradycardia in a young infant. The Pediatric infectious disease journal. 1991;10:340-2.
[31] Xu Y, Li N, Xiang R, Sun P. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends in biochemical sciences. 2014;39:268-76.
[32] Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers. 2019;11.
[33] Zhang YX, Yuan J, Gao ZM, Zhang ZG. LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway. European review for medical and pharmacological sciences. 2018;22:443-9.
[34] Wang P, Chen D, Ma H, Li Y. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 2017;8:84086-101.